Efficacy and tolerability of palliative split-course thoracic chemoradiotherapy for symptomatic non-small cell lung cancer

Virag K. Dandekar, Jennifer Young, Krystyna Kiel, Philip Bonomi, Mary J. Fidler, Marta Batus, David J. Sher

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: To assess the efficacy and tolerability of palliative splitcourse concurrent thoracic chemoradiotherapy (CRT) in patients with incurable locally advanced and metastatic non-small cell lung cancer. Methods: All patients with incurable non-small cell lung cancer and symptomatic thoracic disease treated with palliative split-course CRT between March 2006 and February 2013 at a single institution were included in this retrospective study. The primary endpoint was improvement in presenting thoracic symptoms. Secondary endpoints included toxicity, overall survival, and the cumulative incidence of locoregional failure. Results: Fifty-five patients were identified, of whom 89% had distant metastatic disease at the initiation of treatment. The median radiotherapy dose delivered was 40Gy over 20 fractions. Over 90% of patients were able to complete at least 2 cycles of chemotherapy, and 89% of patients completed the prescribed course of radiotherapy. Forty percent of patients had improvement in all presenting symptoms and 78% experienced improvement in at least 1 symptom. Nine and 2 patients, respectively, experienced grade 1 and 2 esophagitis and 1 patient experienced grade 2 pneumonitis. There were no cases of grade 3 toxicity. With a median follow-up for surviving patients of 4.5 months, the estimated actuarial 6-, 12-, and 24-month overall survival was 56%, 25%, and 13%, respectively. The actuarial 6-, 12-, and 24-month cumulative incidence of locoregional failure was 6%, 14%, and 22%, respectively. Discussion: Split-course CRT allows for early introduction of systemic therapy while providing durable locoregional control with tolerable morbidity and significant improvement in chest symptomatology. This paradigm is a viable model for chest palliation in selected patients with intact performance status.

Original languageEnglish (US)
Pages (from-to)605-609
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Thorax
Radiotherapy
Thoracic Diseases
Survival
Esophagitis
Incidence
Pneumonia
Retrospective Studies
Morbidity
Drug Therapy

Keywords

  • Concurrent chemoradiotherapy
  • Non-small cell
  • Palliation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Efficacy and tolerability of palliative split-course thoracic chemoradiotherapy for symptomatic non-small cell lung cancer. / Dandekar, Virag K.; Young, Jennifer; Kiel, Krystyna; Bonomi, Philip; Fidler, Mary J.; Batus, Marta; Sher, David J.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 6, 01.01.2015, p. 605-609.

Research output: Contribution to journalArticle

Dandekar, Virag K. ; Young, Jennifer ; Kiel, Krystyna ; Bonomi, Philip ; Fidler, Mary J. ; Batus, Marta ; Sher, David J. / Efficacy and tolerability of palliative split-course thoracic chemoradiotherapy for symptomatic non-small cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2015 ; Vol. 38, No. 6. pp. 605-609.
@article{80fc96a5bfa34bb2abcf4a0300a2b7df,
title = "Efficacy and tolerability of palliative split-course thoracic chemoradiotherapy for symptomatic non-small cell lung cancer",
abstract = "Introduction: To assess the efficacy and tolerability of palliative splitcourse concurrent thoracic chemoradiotherapy (CRT) in patients with incurable locally advanced and metastatic non-small cell lung cancer. Methods: All patients with incurable non-small cell lung cancer and symptomatic thoracic disease treated with palliative split-course CRT between March 2006 and February 2013 at a single institution were included in this retrospective study. The primary endpoint was improvement in presenting thoracic symptoms. Secondary endpoints included toxicity, overall survival, and the cumulative incidence of locoregional failure. Results: Fifty-five patients were identified, of whom 89{\%} had distant metastatic disease at the initiation of treatment. The median radiotherapy dose delivered was 40Gy over 20 fractions. Over 90{\%} of patients were able to complete at least 2 cycles of chemotherapy, and 89{\%} of patients completed the prescribed course of radiotherapy. Forty percent of patients had improvement in all presenting symptoms and 78{\%} experienced improvement in at least 1 symptom. Nine and 2 patients, respectively, experienced grade 1 and 2 esophagitis and 1 patient experienced grade 2 pneumonitis. There were no cases of grade 3 toxicity. With a median follow-up for surviving patients of 4.5 months, the estimated actuarial 6-, 12-, and 24-month overall survival was 56{\%}, 25{\%}, and 13{\%}, respectively. The actuarial 6-, 12-, and 24-month cumulative incidence of locoregional failure was 6{\%}, 14{\%}, and 22{\%}, respectively. Discussion: Split-course CRT allows for early introduction of systemic therapy while providing durable locoregional control with tolerable morbidity and significant improvement in chest symptomatology. This paradigm is a viable model for chest palliation in selected patients with intact performance status.",
keywords = "Concurrent chemoradiotherapy, Non-small cell, Palliation",
author = "Dandekar, {Virag K.} and Jennifer Young and Krystyna Kiel and Philip Bonomi and Fidler, {Mary J.} and Marta Batus and Sher, {David J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/COC.0000000000000007",
language = "English (US)",
volume = "38",
pages = "605--609",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Efficacy and tolerability of palliative split-course thoracic chemoradiotherapy for symptomatic non-small cell lung cancer

AU - Dandekar, Virag K.

AU - Young, Jennifer

AU - Kiel, Krystyna

AU - Bonomi, Philip

AU - Fidler, Mary J.

AU - Batus, Marta

AU - Sher, David J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: To assess the efficacy and tolerability of palliative splitcourse concurrent thoracic chemoradiotherapy (CRT) in patients with incurable locally advanced and metastatic non-small cell lung cancer. Methods: All patients with incurable non-small cell lung cancer and symptomatic thoracic disease treated with palliative split-course CRT between March 2006 and February 2013 at a single institution were included in this retrospective study. The primary endpoint was improvement in presenting thoracic symptoms. Secondary endpoints included toxicity, overall survival, and the cumulative incidence of locoregional failure. Results: Fifty-five patients were identified, of whom 89% had distant metastatic disease at the initiation of treatment. The median radiotherapy dose delivered was 40Gy over 20 fractions. Over 90% of patients were able to complete at least 2 cycles of chemotherapy, and 89% of patients completed the prescribed course of radiotherapy. Forty percent of patients had improvement in all presenting symptoms and 78% experienced improvement in at least 1 symptom. Nine and 2 patients, respectively, experienced grade 1 and 2 esophagitis and 1 patient experienced grade 2 pneumonitis. There were no cases of grade 3 toxicity. With a median follow-up for surviving patients of 4.5 months, the estimated actuarial 6-, 12-, and 24-month overall survival was 56%, 25%, and 13%, respectively. The actuarial 6-, 12-, and 24-month cumulative incidence of locoregional failure was 6%, 14%, and 22%, respectively. Discussion: Split-course CRT allows for early introduction of systemic therapy while providing durable locoregional control with tolerable morbidity and significant improvement in chest symptomatology. This paradigm is a viable model for chest palliation in selected patients with intact performance status.

AB - Introduction: To assess the efficacy and tolerability of palliative splitcourse concurrent thoracic chemoradiotherapy (CRT) in patients with incurable locally advanced and metastatic non-small cell lung cancer. Methods: All patients with incurable non-small cell lung cancer and symptomatic thoracic disease treated with palliative split-course CRT between March 2006 and February 2013 at a single institution were included in this retrospective study. The primary endpoint was improvement in presenting thoracic symptoms. Secondary endpoints included toxicity, overall survival, and the cumulative incidence of locoregional failure. Results: Fifty-five patients were identified, of whom 89% had distant metastatic disease at the initiation of treatment. The median radiotherapy dose delivered was 40Gy over 20 fractions. Over 90% of patients were able to complete at least 2 cycles of chemotherapy, and 89% of patients completed the prescribed course of radiotherapy. Forty percent of patients had improvement in all presenting symptoms and 78% experienced improvement in at least 1 symptom. Nine and 2 patients, respectively, experienced grade 1 and 2 esophagitis and 1 patient experienced grade 2 pneumonitis. There were no cases of grade 3 toxicity. With a median follow-up for surviving patients of 4.5 months, the estimated actuarial 6-, 12-, and 24-month overall survival was 56%, 25%, and 13%, respectively. The actuarial 6-, 12-, and 24-month cumulative incidence of locoregional failure was 6%, 14%, and 22%, respectively. Discussion: Split-course CRT allows for early introduction of systemic therapy while providing durable locoregional control with tolerable morbidity and significant improvement in chest symptomatology. This paradigm is a viable model for chest palliation in selected patients with intact performance status.

KW - Concurrent chemoradiotherapy

KW - Non-small cell

KW - Palliation

UR - http://www.scopus.com/inward/record.url?scp=84948564862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948564862&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000007

DO - 10.1097/COC.0000000000000007

M3 - Article

VL - 38

SP - 605

EP - 609

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -